Focal Segmental Glomerulosclerosis (FSGS) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Focal Segmental Glomerulosclerosis (FSGS) – Drugs In Development, 2024 report and make more profitable business decisions.
Focal segmental glomerulosclerosis (FSGS) is a rare kidney disease that causes scarring of the glomeruli, the tiny filters that remove waste from the blood. The scarring affects only some parts of some glomeruli, hence the name “focal segmental”. FSGS can lead to protein loss in the urine, swelling in the body, high cholesterol, and kidney failure. FSGS can have different causes, such as infections, drugs, genetic mutations, or other kidney diseases. Sometimes, the cause is unknown. Treatment for FSGS depends on the type and severity of the disease. It may include medications to reduce proteinuria and blood pressure, dietary changes, dialysis, or kidney transplant.
The Focal Segmental Glomerulosclerosis (FSGS) drugs in development market research report provide comprehensive information on the therapeutics under development for Focal Segmental Glomerulosclerosis (FSGS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Focal Segmental Glomerulosclerosis (FSGS) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Focal Segmental Glomerulosclerosis (FSGS) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 33 molecules, with 32 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Focal Segmental Glomerulosclerosis (FSGS) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Focal Segmental Glomerulosclerosis (FSGS) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Focal Segmental Glomerulosclerosis (FSGS) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acelyrin IncAkebia Therapeutics Inc
Algomedix Inc
Amgen Inc
Anagenics Ltd
Boehringer Ingelheim International GmbH
Ceptur Therapeutics Inc
Certa Therapeutics Pty Ltd
Chinook Therapeutics Inc
Createrna Science and Technology Co Ltd
Delta 4 GmbH
Dimerix Ltd
Eli Lilly and Co
Goldfinch Bio Inc
Horizon Therapeutics Plc
InSilico Medicine
Jiangsu Hansoh Pharmaceutical Group Co Ltd
KBP Biosciences Co Ltd
OccuRx Pty Ltd
Oraxion Therapeutics Inc
Puretech Health Plc
River 3 Renal Corp
Shenzhen Crystal Egg Biomedical Technology Co Ltd
Shenzhen Evergreen Therapeutics Co Ltd
Surrozen Inc
Tohoku University
Travere Therapeutics Inc
Vertex Pharmaceuticals Inc
ZyVersa Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Focal Segmental Glomerulosclerosis (FSGS) reports